MedTrace Logo

Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

NCT01179919 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-02-09

Study results available
· View outcomes & findings →

Summary

One in three Americans are obese. Obese subjects may or may not need higher doses of the anti-flu drug known as Tamiflu (oseltamivir). The current study is being done to see if the FDA approved dose of oseltamivir will achieve similar concentrations in obese healthy volunteers compared to that previously shown in non-obese volunteers.

Conditions

Interventions

DRUG

Oseltamivir

Capsule, 75 mg by mouth for 9 doses

Sponsors & Collaborators

Principal Investigators

  • Manjunath Pai, PharmD · ACPHS

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-09-30
Completion
2010-12-31

Countries

  • United States

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01179919 on ClinicalTrials.gov